Found 93 clinical trials
INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors
, bladder cancer, and specified GI malignancies (defined as CRC, gastric/GEJ cancer, HCC, PDAC, or SCAC)
- 93 views
- 11 Jul, 2022
- 19 locations
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
combinations in participants with metastatic Pancreatic Ductal Adenocarcinoma (PDAC). Two cohorts will be enrolled in parallel in this study: Cohort 1 will consist of patients who have
- 329 views
- 30 Aug, 2023
- 14 locations
Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer (CIRCPAC)
The goal of this clinical trial is to investigate if plasma ctDNA and eccDNA before resection for suspicion of pancreatic ductal adenocarcinoma (PDAC) can predict early recurrence and overall
- 0 views
- 05 Apr, 2023
- 1 location
Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2
pancreatic ductal adenocarcinoma (mPDAC). This study aims to explore whether blockade of Transforming Growth Factor β (TGFβ) in combination with gemcitabine/nab-paclitaxel can reduce fibrosis in PDAC
- 0 views
- 09 Apr, 2023
- 93 locations
A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) (NALPAC)
A non-comparative randomized phase 2 study, evaluating the efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for metastatic pancreatic ductal adenocarcinoma (PDAC), progressive after Gemcitabine
- 0 views
- 04 Oct, 2022
- 1 location
A Study to Evaluate ATP150/ATP152, VSV-GP154 and Ezabenlimab in Patients With KRAS G12D/G12V Mutated PDAC (KISIMA-02)
The goal of this clinical trial is to test an experimental treatment (immunotherapy) in pancreatic cancer patients. The main research objectives are: to evaluate if the KISIMA-02 treatment is safe and well-tolerated (first part) to evaluate if the KISIMA-02 treatment has an impact on the time to observe a possible …
- 0 views
- 22 Aug, 2023
- 5 locations
Evaluation of Polychemotherapy With XELOXIRI-3 in Elderly or Frail Patients With Advanced Pancreatic Adenocarcinoma (ALIX)
Current standard of care for patients with metastatic Pancreatic Ductal AdenoCarcinoma (PDAC) is chemotherapy, preferential regimen being FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and
- 0 views
- 25 May, 2022
- 5 locations
Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours
The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).
- 0 views
- 04 Oct, 2022
- 11 locations
Stereotactic Radiotherapy vs Best Supportive Care in Unfit Pancreatic Cancer Patients (PANCOSAR)
SUMMARY Rationale: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, its incidence increases with age. Many patients with localized (non-metastatic) PC have significant
- 0 views
- 17 Mar, 2022
- 1 location
Pilot Study of a Multimodal Prehabilitation Pancreatic Cancer Program
pancreatic ductal adenocarcinoma (PDAC)
- 0 views
- 28 May, 2021
- 1 location